Use of Finasteride and Minoxidil for the Treatment of Androgenetic Alopecia: A Review

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This review explores different types of alopecia, the effects on hair appearance and growth, and the conventional treatments available, including minoxidil and finasteride, along with their side effects and the need for future drug development and potential therapies.

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

This study suggests that combination therapies including minoxidil with either finasteride, low-level laser light therapy, or microneedling are more effective than minoxidil alone for treating androgenetic alopecia.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This review discusses the potential of herbal treatments like Saw palmetto, Green tea, and Rosemary as alternatives to conventional drugs for androgenetic alopecia, noting that these herbs may inhibit the 5-alpha-reductase enzyme and reduce hair loss with fewer side effects.

In this study, oral finasteride therapy was associated with decreased DHT levels and improved hair loss severity in young male AGA patients, while hormonal changes influenced the curative effect.

This study found that women with female pattern hair loss had increased 5α-reductase isozymes and decreased aromatase mRNA levels, potentially affecting their response to treatment.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This paper discusses the potential relationship between finasteride's adverse effects and factors like hand preference and sexual orientation, suggesting these could influence risk in male androgenic alopecia treatment, but reports no new clinical results.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.